IpsenIPSEF 95 FCF Margin % is 22.94% as of Dec. 2025, which is 52% above its 10-year median of 15.10. GuruFocus rates IPSEF with a GF Score™ of 95/100 and a GF Value™ of $92.81. The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Ipsen ranks better than 89.35% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ipsen's Free Cash Flow for the
six
months ended in Dec. 2025 was $535 Mil. Ipsen's Revenue for the
six
months ended in Dec. 2025 was $2,333 Mil. Therefore, Ipsen's FCF Margin % for the quarter that ended in Dec. 2025 was 22.94%.
The historical rank and industry rank for Ipsen's FCF Margin % or its related term are showing as below:
IPSEF'
s FCF Margin % Range Over the Past 10 Years
Min: -3.26 Med: 15.1 Max: 23.48
Current: 20.63
During the past 13 years, the highest FCF Margin % of Ipsen was 23.48%. The lowest was -3.26%. And the median was 15.10%.
IPSEF's FCF Margin % is ranked better than 89.35% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs IPSEF: 20.63
Ipsen FCF Margin % Related Terms
Ipsen FCF Margin % Historical Data
* Premium members only.
The historical data trend for Ipsen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Ipsen's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen (IPSEF) has a FCF Margin % of 22.94% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ipsen and its competitors. This is 52% above median its historical median of 15.10. According to the industry distribution chart, Ipsen ranks #102 out of 958 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is Ipsen's FCF Margin % too high?
Ipsen's current FCF Margin % of 22.94% is 52% above median its 10-year median of 15.10. The Drug Manufacturers industry median FCF Margin % is 2.51. Ipsen's value of 22.94% is 813.9% above this industry median. Based on the distribution chart, Ipsen ranks #102 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ipsen has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Ipsen's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #102 out of 958 companies for FCF Margin %. This places Ipsen in the top 11% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Ipsen's value of 22.94% is 813.9% above this benchmark. While the company's 10-year median is 15.10 vs. the industry median of 2.51, Ipsen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current FCF Margin % of 22.94% is 813.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current FCF Margin % is 22.94%, which is 52% above median its own 10-year median of 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Ipsen (IPSEF) has a current FCF Margin % of 22.94%. The stock's GF Value™ is $92.81, compared to a current price of $113.13 — trading 21.9% above its estimated fair value. The current FCF Margin % is 22.94%, which is 52% above median its 10-year median of 15.10 and 813.9% above the Drug Manufacturers industry median of 2.51. Ipsen's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ipsen (IPSEF), the current FCF Margin % is 22.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (IPSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of $113.13 is trading 21.9% above its estimated GF Value™ of $92.81.
Key valuation signals for IPSEF:
FCF Margin %: 22.94% (52% above median its 10-year median of 15.10)
GF Value™: $92.81 vs. price of $113.13 (21.9% above fair value)
Industry Position: 813.9% above the Drug Manufacturers median (#102 of 958)
No single metric tells the full story. See the IPSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score
Get the complete analysis for IPSEF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSEF has been successfully added to your 
